Why Inovio Shares Rose 22.6% in May
Inovio Pharmaceuticals (NASDAQ: INO) shares climbed 22.6% in May, according to data from S&P Global Market Intelligence, as investors cheered the rapid development of its coronavirus vaccine and as the company published positive preclinical data.
Inovio in late April said it completed enrollment of 40 healthy volunteers in a phase 1 trial for its coronavirus vaccine and said it expects preliminary data in late June. The company last month announced the publication of preclinical data showing strong neutralizing antibody and T-cell immune responses in animal models.
Image source: Getty Images.
Source Fool.com
